J Cancer Res Clin Oncol 1997, 123:82–90.PubMedCrossRef 164. Perez-Caro M, Cobaleda C, Gonzalez-Herrero I, Vicente-Dueñas C, Bermejo-Rodríguez C, Sánchez-Beato M, Orfao A, Pintado B, Flores T, Sánchez-Martín M, Jiménez R, Piris MA, Sánchez-García I: Cancer induction by restriction of oncogene expression to the stem cell compartment. EMBO J 2009, 28:8–20.PubMedCrossRef 165. Lara PC, Lloret M, Clavo B, Apolinario RM, Henríquez-Hernández LA, Bordón E, Fontes F, Rey A: https://www.selleckchem.com/products/gsk2879552-2hcl.html Severe hypoxia induces chemo-resistance in clinical cervical tumors through MVP over-expression.
Radiat Oncol 2009, high throughput screening 4:29.PubMedCrossRef 166. Elloul S, Vaksman O, Stavnes HT, Trope CG, Davidson B, Reich R: Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions. Clin Exp Metastasis 2010, 27:161–172.PubMedCrossRef 167. Pistollato F, Abbadi S, Rampazzo E, Persano L, Della Puppa A, Frasson C, Sarto E, Scienza R, D’avella D, Basso G: Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. Stem Cells 2010, 28:851–862.PubMedCrossRef 168. Greijer AE, van der Groep P, Kemming D, Shvarts A, Semenza GL, Meijer GA, van de Wiel MA, Belien JA, van Diest PJ, van der Wall E: Upregulation of gene expression by hypoxia is mediated predominantly
by hypoxia-inducible factor Inhibitor Library chemical structure 1 (HIF-1). J Pathol 2005,206(3):291–304.PubMedCrossRef 169. Levine AJ, Puzio-Kuter AM: The control of themetabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010,3(330(6009)):1340–4.CrossRef 170. DeBerardinis RJ: Is cancer a disease of abnormal cellular metabolism? New angles on an old idea. Genet Med 2008, 10:767–777.PubMedCrossRef 171. Smith
LM, Nesterova A, Ryan MC, Duniho S, Jonas M, Anderson M, Zabinski RF, Sutherland MK, Gerber HP, Van Orden KL, Moore PA, Ruben SM, Carter PJ: CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 2008, 99:100–109.PubMedCrossRef 172. Orian-Rousseau V: CD44, a therapeutic target for metastasizing tumours. Eur J Cancer 2010, 46:1271–7.PubMedCrossRef 173. De Stefano I, Battaglia A, Zannoni GF, Prisco MG, Fattorossi A, Travaglia D, Baroni S, Renier D, Scambia G, Ferlini C, Gallo D: Hyaluronic acid-paclitaxel: Oxalosuccinic acid effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts. Cancer Chemother Pharmacol 2011,68(1):107–16.PubMedCrossRef 174. Bretz NP, Salnikov AV, Perne C, Keller S, Wang X, Mierke CT, Fogel M, Erbe-Hofmann N, Schlange T, Moldenhauer G, Altevogt P: CD24 controls Src/STAT3 activity in human tumors. Cell Mol Life Sci 2012,69(22):3863–3879.PubMedCrossRef 175. Su D, Deng H, Zhao X, Zhang X, Chen L, Chen X, Li Z, Bai Y, Wang Y, Zhong Q, Yi T, Qian Z, Wei Y: Targeting CD24 for treatment of ovarian cancer by short hairpin RNA. Cytotherapy 2009,11(5):642–652.PubMedCrossRef 176.